Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District
Objective: analyzing the acquisition and monthly costs for patients on modern fixed-dose antihypertensive combinations in three regions of the Far Eastern Federal District.Material and methods. Intra-group analysis of retail of antihypertensive drugs for 2019 in drugstores of the Khabarovsk Region,...
Published in: | FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology |
---|---|
Main Authors: | , |
Format: | Article in Journal/Newspaper |
Language: | Russian |
Published: |
IRBIS LLC
2021
|
Subjects: | |
Online Access: | https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.061 https://doaj.org/article/159f814b748748e394472bd6e126a30b |
id |
ftdoajarticles:oai:doaj.org/article:159f814b748748e394472bd6e126a30b |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:159f814b748748e394472bd6e126a30b 2023-05-15T18:09:15+02:00 Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District M. S. Soboleva E. E. Loskutova 2021-04-01T00:00:00Z https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.061 https://doaj.org/article/159f814b748748e394472bd6e126a30b RU rus IRBIS LLC https://www.pharmacoeconomics.ru/jour/article/view/485 https://doaj.org/toc/2070-4909 https://doaj.org/toc/2070-4933 2070-4909 2070-4933 doi:10.17749/2070-4909/farmakoekonomika.2021.061 https://doaj.org/article/159f814b748748e394472bd6e126a30b Фармакоэкономика, Vol 14, Iss 1, Pp 41-49 (2021) arterial hypertension cost of therapy fixed-dose combinations regions of the far eastern federal district Therapeutics. Pharmacology RM1-950 Economics as a science HB71-74 article 2021 ftdoajarticles https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.061 2023-03-19T01:40:42Z Objective: analyzing the acquisition and monthly costs for patients on modern fixed-dose antihypertensive combinations in three regions of the Far Eastern Federal District.Material and methods. Intra-group analysis of retail of antihypertensive drugs for 2019 in drugstores of the Khabarovsk Region, Sakhalin Region, Amur Region (n=100) was carried out. The calculation of the monthly cost of therapy was performed and total sales indicators were identified. Statistical analysis: dispersion analysis, Spearman's rank correlation coefficient, Kruskal–Wallis test.Results. The maximum demand in patients among combinations of -blockers in the price range of 100-500 rubles: atenolol+chlortalidone; bisoprolol+amlodipine. In the grope of combinations of angiotensin-converting enzyme inhibitors with diuretics/calcium channel blockers, the most often acquired were: perindopril/ramipril+indapamide/amlodipine, enalapril+hydrochlorothiazide – in the price segment of 500–1000 rubles. Preferences for the use of combinations of angiotensin II receptor blockers+diuretic/calcium channel blockers: valsartan+amlodipine with a monthly cost of therapy of 300–500 rubles; losartan+hydrochlorothiazide – 100–500 rubles and azilsartan+chlortalidonee – 500–1000 rubles. The most popular three-component drugs were valsartan+amlodipine+hydrochlorothiazide, perindopril+amlodipine+indapamide with a monthly cost over 500 rubles. Differences in the acquisition structure of fixed-dose antihypertensive combinations between regions were statistically significant.Conclusion. The share of sales of combined antihypertensive drugs remains insignificant. The main selection criteria within an international nonproprietary name are affordability or trust in a brand. The presence of a reliable correlation of the acquisition structure with the region proves the influence of regional preferences of specialists in drug prescribing. Article in Journal/Newspaper Sakhalin Directory of Open Access Journals: DOAJ Articles FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology 14 1 41 49 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
Russian |
topic |
arterial hypertension cost of therapy fixed-dose combinations regions of the far eastern federal district Therapeutics. Pharmacology RM1-950 Economics as a science HB71-74 |
spellingShingle |
arterial hypertension cost of therapy fixed-dose combinations regions of the far eastern federal district Therapeutics. Pharmacology RM1-950 Economics as a science HB71-74 M. S. Soboleva E. E. Loskutova Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District |
topic_facet |
arterial hypertension cost of therapy fixed-dose combinations regions of the far eastern federal district Therapeutics. Pharmacology RM1-950 Economics as a science HB71-74 |
description |
Objective: analyzing the acquisition and monthly costs for patients on modern fixed-dose antihypertensive combinations in three regions of the Far Eastern Federal District.Material and methods. Intra-group analysis of retail of antihypertensive drugs for 2019 in drugstores of the Khabarovsk Region, Sakhalin Region, Amur Region (n=100) was carried out. The calculation of the monthly cost of therapy was performed and total sales indicators were identified. Statistical analysis: dispersion analysis, Spearman's rank correlation coefficient, Kruskal–Wallis test.Results. The maximum demand in patients among combinations of -blockers in the price range of 100-500 rubles: atenolol+chlortalidone; bisoprolol+amlodipine. In the grope of combinations of angiotensin-converting enzyme inhibitors with diuretics/calcium channel blockers, the most often acquired were: perindopril/ramipril+indapamide/amlodipine, enalapril+hydrochlorothiazide – in the price segment of 500–1000 rubles. Preferences for the use of combinations of angiotensin II receptor blockers+diuretic/calcium channel blockers: valsartan+amlodipine with a monthly cost of therapy of 300–500 rubles; losartan+hydrochlorothiazide – 100–500 rubles and azilsartan+chlortalidonee – 500–1000 rubles. The most popular three-component drugs were valsartan+amlodipine+hydrochlorothiazide, perindopril+amlodipine+indapamide with a monthly cost over 500 rubles. Differences in the acquisition structure of fixed-dose antihypertensive combinations between regions were statistically significant.Conclusion. The share of sales of combined antihypertensive drugs remains insignificant. The main selection criteria within an international nonproprietary name are affordability or trust in a brand. The presence of a reliable correlation of the acquisition structure with the region proves the influence of regional preferences of specialists in drug prescribing. |
format |
Article in Journal/Newspaper |
author |
M. S. Soboleva E. E. Loskutova |
author_facet |
M. S. Soboleva E. E. Loskutova |
author_sort |
M. S. Soboleva |
title |
Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District |
title_short |
Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District |
title_full |
Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District |
title_fullStr |
Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District |
title_full_unstemmed |
Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District |
title_sort |
analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the far eastern federal district |
publisher |
IRBIS LLC |
publishDate |
2021 |
url |
https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.061 https://doaj.org/article/159f814b748748e394472bd6e126a30b |
genre |
Sakhalin |
genre_facet |
Sakhalin |
op_source |
Фармакоэкономика, Vol 14, Iss 1, Pp 41-49 (2021) |
op_relation |
https://www.pharmacoeconomics.ru/jour/article/view/485 https://doaj.org/toc/2070-4909 https://doaj.org/toc/2070-4933 2070-4909 2070-4933 doi:10.17749/2070-4909/farmakoekonomika.2021.061 https://doaj.org/article/159f814b748748e394472bd6e126a30b |
op_doi |
https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.061 |
container_title |
FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology |
container_volume |
14 |
container_issue |
1 |
container_start_page |
41 |
op_container_end_page |
49 |
_version_ |
1766181731110486016 |